Opendata, web and dolomites

PORTAL SIGNED

Personalized oncology for refractory and relapsed lymphoma using humanized patient derived othotopic xenografts (ImmunePDOX)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PORTAL project word cloud

Explore the words cloud of the PORTAL project. It provides you a very rough idea of what is the project "PORTAL" about.

training    solid    hematological    pharmaceuticals    re    interventions    therapy    oncology    initiating    worked    line    patient    reflects    director    foundation    clinical    brazil    europdx    models    priorities    strategy    multidisciplinary    oswaldo    qualitative    chemotherapy    ico    combined    refractory    remained    original    treatment    dr    relapsed    ana    service    biomedical    infection    leader    catalan    hematology    proof    mechanisms    career    humanized    orthotopic    fiocruz    reintegrated    portal    programmed    researcher    educational    relevantly    farre    board    position    contributed    12    barcelona    spin    alberto    supervised    xenograft    public    overcoming    option    lourdes    sureda    xenopat    scientific    resistance    group    villanueva    lymphoma    policy    engagement    idibell    besides    off    spain    cruz    preclinical    htlv    acquired    2020    head    bellvitge    lymphomas    cancers    paradigm    innovative    privileged    always    maturity    independent    incorporate    transfer    personalized    empiric    therapeutic    improvement    of    she    gender   

Project "PORTAL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 170˙121.00

Map

 Project objective

This proposal is a “PORTAL” to re-incorporate Dr. Lourdes Farre from the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil to Europe at the Catalan Institute of Oncology (ICO), a part of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. She will be supervised by Dr. Alberto Villanueva, leader of the Resistance, Chemotherapy and Orthotopic Xenograft Models Group and Director Board of the EuroPDX (www.europdx.eu) in collaboration with Dr. Ana Sureda, Head of the Hematology Department (ICO). Dr. Farre worked at FIOCRUZ for 12 years where she relevantly contributed in lymphoma research and acquired maturity as an independent researcher. Dr. Farre will contribute to ICO/IDIBELL initiating a new research line in resistance in hematological cancers and transfer her knowledge in HTLV-1 infection. She will also contribute to the ICO Hematology Service with a personalized oncology strategy for clinical oncology practice. Knowledge and preclinical models could be transfer to the IDIBELL`s spin-off Xenopat and Pharmaceuticals. She will have access to a solid multidisciplinary training program that will provide qualitative improvement on her career and a privileged position to be reintegrated in a long term research position in Europe. She has always combined scientific activity with educational interventions. Besides scientific dissemination, she programmed public engagement activities. This proposal is a proof-of-concept of personalized oncology for refractory/relapsed lymphoma and aims to study the mechanisms involved in response to therapy using preclinical humanized orthotopic models. Relapsed/refractory lymphomas represent a major treatment challenge and general treatment paradigm has remained empiric. Defining the best therapeutic option for each patient and overcoming such resistance is a priority. Humanized and orthotopic approach is original and innovative. PORTAL reflects the policy priorities of the Europe 2020 strategy and considers gender issues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PORTAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PORTAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More